Q2 2026 saw 38% revenue growth to $753M, with test volumes and gross margin both rising year-over-year. Oncology and women's health segments drove strong performance, and 2026 revenue guidance was raised by $100M at the midpoint.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.